Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin’s Lymphoma: The Tei Index Evaluation

Agata Puzzovivo,Agnese Maria Fioretti,Carla Minoia,Roberta Villoni,Santa Carbonara,Giusi Graziano,Fabio Pavone,Attilio Guarini,Stefano Oliva
DOI: https://doi.org/10.3390/jpm12020290
IF: 3.5083
2022-02-16
Journal of Personalized Medicine
Abstract:Anthracyclines are widely employed in lymphoma’s chemotherapy and has been shown to induce heart failure. Echocardiographic parameters of left ventricular (LV) systolic function are usually used to monitor the cardiac side effects during and after anthracyclines treatment. The measurement of theTei index could anticipate the onset of LV dysfunction. The aim of this study was to evaluate the performance of the delta Tei index for the early detection of cardiac toxicity in a prospective population of anthracycline-treated lymphoma patients. Our preliminary data suggest that the Tei index may predict the risk for cardiotoxicity in this subset of patients earlier than LV ejection fraction alteration.
medicine, general & internal,health care sciences & services
What problem does this paper attempt to address?